This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...

The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the ...

The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...

The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about pharmaceutical ...

In fact, the price of such vouchers has been climbing steadily in recent months, according to public disclosures surrounding ...

As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Unlike VantAI, Amneal has kept its name, focusing its changes instead on its visual identity. The company, which sells ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...